• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

News You Might Have Missed: Dec 5th 2022

Microdose NewsDesk by Microdose NewsDesk
December 5, 2022
in Don't Miss
Reading Time: 2 mins read
A A

 

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.

 

Protests in Ottawa for Access to Psychedelic Medicine

Non-profit group TheraPsil has brought a group of patients and medical professionals across Canada to Ottawa to fight for medical access to psilocybin mushrooms.

[bsa_pro_ad_space id=2]
ADVERTISEMENT

The intent is to engage with policymakers and the public around well-established potential benefits of psilocybin for end-of-life anxiety, depression and PTSD. A protest was held at 1 pm on Nov 29th and 30th, 2022, at Parliament Hill in Ottawa.

Continue on your trip...

SoundSelf’s Wefunder Campaign: Bringing Digital Psychedelics to Mental Health Providers

News You Might Have Missed: Dec 18th, 2023

News You Might Have Missed: Dec 4th, 2023

 

 

DEA Increases Production Quotas for Psychedelics

The Drug Enforcement Administration (DEA) has released its production quotas for 2023, announcing an increase in the permitted quantity of psychedelic compounds manufactured for research purposes. This is good news, as the increase will make it that much easier for researchers to continue their work.

 

 

Numinus Wellness Reports Q4 2022 and Annual Results

“Fiscal 2022 was a pivotal year for Numinus, as we entered the US market with the transformational acquisition of Novamind, expanded our Ketamine-assisted Therapy offering across Canada, launched a formal practitioner training program, and unveiled a global rebranding of our company.”

Direct Online Lasix Purchase

Payton Nyquvest, Founder and CEO.

  • Q4 2022 revenues grew 643% year-over-year to $4.2 million
  • Q4 2022 gross margin grew to 31.5%, generated $1.3 million of gross profit
  • Completed acquisition of Novamind, positioning Numinus as a leading, integrated mental healthcare company providing psychedelic-assisted therapies
  • Ended quarter with cash position of $33.0 million

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT

 

New Study Shows Psychedelics Lowers Barriers to Higher Brain States

A new study shows that psychedelics lower the energy needed to reach higher levels of consciousness. A recent study conducted by Cornell University has shown that psychedelics might lower the energy threshold brain networks require in order to shift to different configurations. How is this possible? The theories and models surrounding such findings are going to be illustrated in this article, which also provides an outline of the results of the study.

 

Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed

 

Tags: News
Microdose NewsDesk

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Next Post
MY Self Ketamine Clinic Launches Ketamine Access Nonprofit

MY Self Ketamine Clinic Launches Ketamine Access Nonprofit

Please login to join discussion

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.